Gilead Sciences Canada, Inc.
6711 Mississauga Road
Suite 202
Mississauga
Ontario
L5N 2W3
Canada
Tel: 905-363-8008
Fax: 905-363-8049
Website: http://www.gilead.ca/
About Gilead Sciences Canada, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Key Contacts: John C. Martin, PhD, Chairman and Chief Executive Officer John F. Milligan, PhD, President and Chief Operating Officer Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer Kevin Young, Executive Vice President, Commercial Operations
Kristen Metza, Senior Vice President, Human Resources Susan Hubbard, Vice President, Investor Relations Amy Flood, Senior Director, Public Affairs
4 articles about Gilead Sciences Canada, Inc.
-
Gilead Canada launches national educational and screening initiative to address Hepatitis C infections
11/30/2021
Gilead Sciences Canada, Inc. announced the launch of Take a 15-Minute Break. For You., a nationwide campaign dedicated to increasing awareness of and screening for the Hepatitis C Virus within underserved communities.
-
Health Canada Issues Notice of Compliance for TRODELVY®, a New Treatment Option for an Aggressive Type of Metastatic Breast Cancer
11/25/2021
Gilead Sciences Canada, Inc. announced that Health Canada has granted Notice of Compliance to TRODELVY® for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior therapies, at least one of them for metastatic disease.[ii].
-
Gilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy
2/19/2019
YESCARTA is a chimeric antigen receptor T (CAR T) cell therapy that is custom-made for each patient from his or her own T cells.
-
Gilead Sciences Canada, Inc. Release: Quebec Becomes First Province To Reimburse Sovaldi® For The Treatment Of Chronic Hepatitis C
6/3/2014